Efficacy of amlodipin in treatment of arterial hypertension.


Cite item

Full Text

Abstract

The article summarizes the available data on amlodipin in hypertensive patients of high cardiovascular risk. The results of studies
demonstrate strong and long-lasting antihypertensive effect of ramipril. Moreover, amlodipin treatment decreases cardiovascular events
rate, damage of target organs and atherosclerosis progression. Amlodipin shows both high efficacy and good safety. All this properties
make amlodipin extremely attractive for the everyday practice.

About the authors

Elena Adamovna Prokhorovich

References

  1. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваск. тер. и проф. Прил. 2. 2008; 7 (6).
  2. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia, 1998; p. 1-26.
  3. Leenen FHH, Fourney A, Notman G, Tanner J. Persistence of antihypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs short (diltiazem) harf-life. Br J Clin Pharmacol 1996; 41: 83-8.
  4. Zannad F, Bernaud CM, Fay R. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24h therapeutic coverage and beyond in patients with mild to moderate hypertension. J Hyperten 1999; 17: 137-46.
  5. http://www.docguide.com
  6. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Pressure 1996; 5: 206-8.
  7. Siche JP et al. Effects of amlodipine on baroreflex and sympathetic nervous system activity in mild-to-moderate hypertension. Am J Hypertens 2001; 14 (5 Pt 1): 424-8.
  8. Susaguri M et al. Amlodipine lowers blood pressure without increasing sympathetic activity or activating the rennin-angiotensin system in patients with essential hypertension. Eur J Clin Pharmacol 1997; 53 (3-4): 197-201.
  9. Фельдшерова Н.А., Семернин Е.Н. Амлодипин: обзор клинических исследований. Кач. клинич. практ. 2002; 2: 27-33.
  10. Neaton JD, Grimm RH, Prineas RJ et al. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270: 713-24.
  11. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
  12. Islim IF, Watson RD, Ihenacho HNC et al. Amlodipine: Effective for treatment of Mild to Moderate Essential Hypertension and Left Ventricular Hypertrophy. Cardiology 2001; 96: 10-8.
  13. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-75.
  14. Pitt B et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503-10.
  15. Nissen S, Tuzcu E, Libby P et al. Effects of antihypertensive drugs on cardiovascular events in patients with coronary heart disease and normal blood pressure. Randomized controlled CAMELOT study. JAMA 2004; 292 (18): 2217-26.
  16. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an Antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofluazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
  17. Sever PS, Dahlof B, Poultier NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
  18. Преображенский Д.В., Сидоренко Б.А., Шабаева Е.Н. Амлодипин - антагонист кальция III поколения. Кардиология. 1998; 2: 66-73.
  19. Белоусов Ю.Б., Леонова М.В. Антагонисты кальция пролонгированного действия и сердечно-сосудистая заболеваемость: Новые данные доказательной медицины. Кардиология. 2001; 4: 87-93
  20. Jorgensen B, Thaulow E. Effects of amlodipine on ischemia after percutaneuos transluminal coronary angioplasty: Secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study. Am Heart J 2003; 145: 1030-5.
  21. http://www.lvrach.ru
  22. Packer M, O'Connor C, Ghali J et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 1996; 335: 1107-14.
  23. Ушкалова Е.А. Фармакологические свойства амлодипина - антагониста кальция последнего поколения. Кардиология. 2004; 14: 91.
  24. Терещенко С.Н., Жиров И.В. Место амлодипина в лечении хронической сердечной недостаточности у женщин. Пробл. женск. здор. 2007; 2 (4): 17-22.
  25. Чазова И.Е., Ратова Л.Г. Лечение артериальной гипертонии у больных с метаболическим синдромом. Системные гипертензии. 2008; 1: 39-43.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 83918 от 12.09.2022 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 83917 от 12.09.2022 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies